NCT01203072View on ClinicalTrials.gov

A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

PHASE2CompletedINTERVENTIONAL
Enrollment

523

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

July 31, 2008

Conditions
Venous ThromboembolismDeep Vein ThrombosisTotal Knee Arthroplasty
Interventions
DRUG

DU-176b

DU-176b 5mg tablets oral, once daily for 2 weeks

DRUG

DU-176b

DU-176b 15mg tablets, oral once daily for 2 weeks

DRUG

DU-176b

DU-176b 30 mg tablets, oral, once daily for 2 weeks

DRUG

DU-176b

DU-176b 60 mg tablets, oral, once daily for 2 weeks

DRUG

Placebo

Matching placebo oral tablets, once daily for 2 weeks

Trial Locations (2)

Unknown

Osaka

Tokyo

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY